Latest & greatest articles for hepatitis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hepatitis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hepatitis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hepatitis

101. Tardus parvus waveforms in Doppler ultrasonography for hepatic artery stenosis after liver transplantation: can a new cut-off value guide the next step?

Tardus parvus waveforms in Doppler ultrasonography for hepatic artery stenosis after liver transplantation: can a new cut-off value guide the next step? 29063132 2018 11 13 2366-0058 43 7 2018 Jul Abdominal radiology (New York) Abdom Radiol (NY) Tardus parvus waveforms in Doppler ultrasonography for hepatic artery stenosis after liver transplantation: can a new cut-off value guide the next step? 1634-1641 10.1007/s00261-017-1358-2 Considering the high false-positive diagnosis of the tardus (...) parvus waveform (TPW) in Doppler ultrasonography (DUS) for hepatic artery stenosis (HAS) after liver transplantation (LT), this study aimed to determine clinical features and new cut-off values to help guide treatment. This retrospective study was approved by an Institutional Review Board. A total of 171 LT recipients were included and underwent DUS and either computed tomography angiography or digital subtraction angiography with an interval < 4 weeks at least 1 month post-LT. The DUS of 69 patients

Abdominal radiology (New York)2017 Full Text: Link to full Text with Trip Pro

102. Safety and efficacy of intra-arterial hepatic chemotherapy with doxorubicin-loaded nanoparticles in hepatocellular carcinoma

Safety and efficacy of intra-arterial hepatic chemotherapy with doxorubicin-loaded nanoparticles in hepatocellular carcinoma 29104762 2018 11 13 2059-7029 2 4 2017 ESMO open ESMO Open Safety and efficacy of intra-arterial hepatic chemotherapy with doxorubicin-loaded nanoparticles in hepatocellular carcinoma. e000238 10.1136/esmoopen-2017-000238 Doxorubicin Transdrug (DT), a nanoformulation of doxorubicin, was demonstrated to overcome the chemoresistance of hepatocellular carcinoma (HCC) in (...) preclinical models. Its efficacy and safety were thus investigated in phase I and randomised phase II trials in unresectable HCC. Phase I was a single dose of DT through the hepatic intra-arterial (HIA) route, dose-escalating 3+3 trial, evaluating five-dose levels from 10 to 40 mg/m 2 with maximal tolerated dose (MTD) as primary endpoint. The multicentre phase II trial randomly assigned (2:1 ratio) patients to receive either 30 mg/m 2 of DT through HIA route every 4 weeks for up to three courses or best

ESMO open2017 Full Text: Link to full Text with Trip Pro

103. Curing Hepatitis C Virus Infection: Best Practices From the U.S. Department of Veterans Affairs.

Curing Hepatitis C Virus Infection: Best Practices From the U.S. Department of Veterans Affairs. The U.S. Department of Veterans Affairs (VA) is the nation's largest care provider for hepatitis C virus (HCV)-infected patients and is uniquely suited to inform national efforts to eliminate HCV. An extensive array of delivery of services, policy guidance, outreach efforts, and funding has broadened the reach and capacity of the VA to deliver direct-acting antiviral (DAA) HCV therapy, supported

Annals of Internal Medicine2017

104. Sofosbuvir/velpatasvir (Epclusa) - Treatment of chronic hepatitis C virus (HCV) infection in adults

Sofosbuvir/velpatasvir (Epclusa) - Treatment of chronic hepatitis C virus (HCV) infection in adults

Scottish Medicines Consortium2017

105. Assessing the impact and cost-effectiveness of needle/syringe provision and opiate substitution therapy on hepatitis C transmission among people who inject drugs in the United Kingdom: analysis of pooled datasets and economic modelling

Assessing the impact and cost-effectiveness of needle/syringe provision and opiate substitution therapy on hepatitis C transmission among people who inject drugs in the United Kingdom: analysis of pooled datasets and economic modelling Assessing the impact and cost-effectiveness of needle/syringe provision and opiate substitution therapy on hepatitis C transmission among people who inject drugs in the United Kingdom: analysis of pooled datasets and economic modelling Journals Library An error (...) occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> {{metadata.Title}} {{metadata.Headline}} Assessing the impact and cost-effectiveness of needle and syringe provision and opioid substitution therapy on hepatitis C transmission among people

NIHR HTA programme2017

107. Hepatitis C Virus Exposure Rate among Health-care Workers in Rural Lower Egypt Governorates

Hepatitis C Virus Exposure Rate among Health-care Workers in Rural Lower Egypt Governorates 29085789 2018 11 13 2450-131X 5 3 2017 Sep Journal of translational internal medicine J Transl Int Med Hepatitis C Virus Exposure Rate among Health-care Workers in Rural Lower Egypt Governorates. 164-168 10.1515/jtim-2017-0024 Studies on hepatitis C virus (HCV) in Egypt supported a strong role for various exposures in the health-care setting. In this study, we attempted to estimate the frequency of HCV (...) of included HCWs was 33.0 ± 9.8 years; of them, 319 (56.56%) were males and 245 (43.44%) were females. The mean duration of health-care work was 9.3 ± 6.7 years. The frequency of antibody against hepatitis C virus (anti-HCV) among included HCWs was 8.7% ( n = 49). Old age and prolonged duration of health-care work were significantly associated with anti-HCV seropositivity. Forty (81.63%) of 49 with anti-HCV-positive HCWs had positive hepatitis C viremia. The frequency of HCV RNA positivity increased

Journal of translational internal medicine2017 Full Text: Link to full Text with Trip Pro

108. Upgrade Combination Response Is Limited by Prolonged Nucelos(t)ide Analogue Therapy in HBeAg-positive Chronic Hepatitis B: A Real-life Study

Upgrade Combination Response Is Limited by Prolonged Nucelos(t)ide Analogue Therapy in HBeAg-positive Chronic Hepatitis B: A Real-life Study 29577027 2018 11 14 2225-0719 6 1 2018 Mar 28 Journal of clinical and translational hepatology J Clin Transl Hepatol Upgrade Combination Response Is Limited by Prolonged Nucelos(t)ide Analogue Therapy in HBeAg-positive Chronic Hepatitis B: A Real-life Study. 11-17 10.14218/JCTH.2017.00020 Background and Aims: Few previous studies have reported (...) on a combination response (hepatitis B virus (HBV) DNA undetected, alanine aminotransferase normalization and hepatitis B e antigen (HBeAg) seroconversion) following nucleos(t)ide analogue (NAs) long-term therapy in patients with chronic hepatitis B (CHB). This study aimed to investigate the combination response on long-term NAs therapy in patients with HBeAg-positive CHB and to determine whether prolonged therapy is beneficial for combination response, particularly in optimal patients (baseline alanine

Journal of clinical and translational hepatology2017 Full Text: Link to full Text with Trip Pro

109. Hepatic Venous Pressure Gradient Measurement in Bangladeshi Cirrhotic Patients: A Correlation with Child’s Status, Variceal Size, and Bleeding

Hepatic Venous Pressure Gradient Measurement in Bangladeshi Cirrhotic Patients: A Correlation with Child’s Status, Variceal Size, and Bleeding 29201796 2018 11 13 2231-5047 7 2 2017 Jul-Dec Euroasian journal of hepato-gastroenterology Euroasian J Hepatogastroenterol Hepatic Venous Pressure Gradient Measurement in Bangladeshi Cirrhotic Patients: A Correlation with Child's Status, Variceal Size, and Bleeding. 142-145 10.5005/jp-journals-10018-1235 Hepatic venous pressure gradient (HVPG (...) ) reflects the portal pressure in patients with cirrhotic portal hypertension. The aim of the study was to assess the relation of HVPG to variceal size, Child-Pugh status, and variceal bleeding. A total of 96 patients with cirrhosis of liver were enrolled prospectively and each patient's HVPG level was measured via the transfemoral route. Clinical and biochemical evaluation and upper gastrointestinal (GI) endoscopy were done in each subject. Severity of cirrhosis was assessed by Child's status. The mean

Euroasian journal of hepato-gastroenterology2017 Full Text: Link to full Text with Trip Pro

110. Hemochromatosis Gene Polymorphism as a Predictor of Sustained Virological Response to Antiviral Treatment in Egyptian Chronic Hepatitis C Patients

Hemochromatosis Gene Polymorphism as a Predictor of Sustained Virological Response to Antiviral Treatment in Egyptian Chronic Hepatitis C Patients 29201799 2018 11 13 2231-5047 7 2 2017 Jul-Dec Euroasian journal of hepato-gastroenterology Euroasian J Hepatogastroenterol Hemochromatosis Gene Polymorphism as a Predictor of Sustained Virological Response to Antiviral Treatment in Egyptian Chronic Hepatitis C Patients. 154-157 10.5005/jp-journals-10018-1238 The aim of this article is to assess HFE (...) C282Y gene mutations as a predictor of sustained virological response (SVR) to anti-hepatitis C virus (HCV) treatment in Egyptian patients. One hundred and forty chronic hepatitis C (CHC) patients were divided into two groups: 70 patients achieved SVR and 70 patients were nonresponders (NRs). All patients were subjected to quantitative polymerase chain reaction (PCR) at baseline, 12 and 24 weeks after therapy commencement. Deoxyribonucleic acid (DNA) sequencing for HFE (C282Y) was done

Euroasian journal of hepato-gastroenterology2017 Full Text: Link to full Text with Trip Pro

111. Viral Hepatitis in South Korea

Viral Hepatitis in South Korea 29201801 2018 11 13 2231-5047 7 2 2017 Jul-Dec Euroasian journal of hepato-gastroenterology Euroasian J Hepatogastroenterol Viral Hepatitis in South Korea. 163-165 10.5005/jp-journals-10018-1240 In South Korea (S. Korea), viral hepatitis is a major public health burden. Advances in healthcare policy, evidence-based medicine, and therapeutic strategies in S. Korea have brought a rapid change in the sociodemographic and clinical characteristics of viral hepatitis (...) . This review discusses the innovative approaches that S. Korea has taken to curb the epidemic of viral hepatitis. In addition, the efficacy of various preventive and therapeutic modalities is discussed. This review aims to provide a brief overview to guide future research direction and healthcare policy changes. How to cite this article: Pak SC, Alastal Y, Khan Z, Darr U. Viral Hepatitis in South Korea. Euroasian J Hepato-Gastroenterol 2017;7(2):163-165. C Pak Stella S Department of Medicine, University

Euroasian journal of hepato-gastroenterology2017 Full Text: Link to full Text with Trip Pro

112. Hepatic Metastasis from Colorectal Cancer

Hepatic Metastasis from Colorectal Cancer 29201802 2018 11 13 2231-5047 7 2 2017 Jul-Dec Euroasian journal of hepato-gastroenterology Euroasian J Hepatogastroenterol Hepatic Metastasis from Colorectal Cancer. 166-175 10.5005/jp-journals-10018-1241 The liver is the most common site of metastasis in patients with colorectal cancer due to its anatomical situation regarding its portal circulation. About 14 to 18% of patients with colorectal cancer present metastasis at the first medical (...) treatment is <8 months from the moment of its presentation, and a survival rate at 5 years of 11% is the best prognosis for those who present with local metastasis. Even in patients with limited metastatic disease, 5-year survival is exceptional. Patients with hepatic metastasis of colorectal cancer have a median survival of 5 to 20 months with no treatment. Approximately 20 to 30% of patients with colorectal metastasis have disease confined to the liver, and this can be managed with surgery. Modern

Euroasian journal of hepato-gastroenterology2017 Full Text: Link to full Text with Trip Pro

113. Knowledge, attitudes and practices toward prevention of hepatitis B virus infection among medical students at Northern Border University, Arar, Kingdom of Saudi Arabia

Knowledge, attitudes and practices toward prevention of hepatitis B virus infection among medical students at Northern Border University, Arar, Kingdom of Saudi Arabia 29038726 2018 11 13 2008-5842 9 9 2017 Sep Electronic physician Electron Physician Knowledge, attitudes and practices toward prevention of hepatitis B virus infection among medical students at Northern Border University, Arar, Kingdom of Saudi Arabia. 5388-5394 10.19082/5388 Health care workers' risk of occupational exposure (...) to HBV is a chief concern, particularly with young students in the health profession. This study was carried out to assess the knowledge regarding symptoms, risk factors and prevention of hepatitis B virus infection among medical students. A cross-sectional study was carried out from November 01, 2016 to May 30, 2017 on medical students at the Northern Border University (Arar, Kingdom of Saudi Arabia). Data were collected from 200 students from all academic years using pre-designed questionnaire

Electronic physician2017 Full Text: Link to full Text with Trip Pro

114. Efficacy and Safety of Rituximab in Hepatitis B Virus–Associated PLA2R-Positive Membranous Nephropathy

Efficacy and Safety of Rituximab in Hepatitis B Virus–Associated PLA2R-Positive Membranous Nephropathy 29725654 2018 11 14 2468-0249 3 2 2018 Mar Kidney international reports Kidney Int Rep Efficacy and Safety of Rituximab in Hepatitis B Virus-Associated PLA2R-Positive Membranous Nephropathy. 486-491 10.1016/j.ekir.2017.09.009 Berchtold Lena L Inserm, UMR_S 1155, Paris, France. Sorbonne Universités, Université Pierre et Marie Curie University of Paris 06, Paris, France. Department of Internal

Kidney international reports2017 Full Text: Link to full Text with Trip Pro

115. Hepatitis E: Still Waters Run Deep

Hepatitis E: Still Waters Run Deep 29577031 2018 11 14 2225-0719 6 1 2018 Mar 28 Journal of clinical and translational hepatology J Clin Transl Hepatol Hepatitis E: Still Waters Run Deep. 40-47 10.14218/JCTH.2017.00030 Hepatitis E is an infectious inflammatory disease of the liver caused by the hepatitis E virus (HEV), a single-stranded RNA virus. Today, it is estimated that there are more than 20 million HEV infections every year, leading to 3.3 million symptomatic cases and more than 56,000 (...) in immunocompromised patients where it can cause chronic liver disease. This article comprehensively reviews current literature to give an overview on clinically important topics. It will focus on epidemiological aspects, acute and chronic HEV infection as well as extra-hepatic manifestations, diagnostic approach and treatment options. Furthermore, the article is concluded with a brief outlook on perspectives and urgent problems to be addressed in the future. von Wulffen Moritz M Department of Medicine I

Journal of clinical and translational hepatology2017 Full Text: Link to full Text with Trip Pro

116. Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on hepatic fibrosis

Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on hepatic fibrosis 29404501 2018 11 13 2471-254X 1 9 2017 11 Hepatology communications Hepatol Commun Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on hepatic fibrosis. 928-945 10.1002/hep4.1104 The farnesoid X receptor (FXR) agonist, a bile acid-activated nuclear receptor, has been shown to improve the histologic features of nonalcoholic steatohepatitis (NASH (...) ); however, a satisfactory effect on hepatic fibrosis has not been achieved. We aimed to investigate the combined effect of FXR agonist and angiotensin II type 1 receptor blocker on hepatic fibrogenesis in rat models of NASH. For 8 weeks, two rat models of NASH were developed. Otsuka Long-Evans Tokushima Fatty (OLETF) rats were administered intraperitoneal injections of 1 mL/kg pig serum (PS) twice a week, whereas Fischer-344 rats were fed a choline-deficient, L-amino acid-defined diet (CDAA

Hepatology communications2017 Full Text: Link to full Text with Trip Pro

117. Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs.

Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs. BACKGROUND: Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugsNeedle syringe programmes (NSP) and opioid substitution therapy (OST) are the primary interventions to reduce hepatitis C (HCV) transmission in people who inject drugs. There is good evidence for the effectiveness of NSP and OST

Cochrane2017

118. Direct-acting antivirals for chronic hepatitis C.

Direct-acting antivirals for chronic hepatitis C. BACKGROUND: Millions of people worldwide suffer from hepatitis C, which can lead to severe liver disease, liver cancer, and death. Direct-acting antivirals (DAAs), e.g. sofosbuvir, are relatively new and expensive interventions for chronic hepatitis C, and preliminary results suggest that DAAs may eradicate hepatitis C virus (HCV) from the blood (sustained virological response). Sustained virological response (SVR) is used by investigators (...) CRITERIA: Randomised clinical trials comparing DAAs versus no intervention or placebo, alone or with co-interventions, in adults with chronic HCV. We included trials irrespective of publication type, publication status, and language. DATA COLLECTION AND ANALYSIS: We used standard methodological procedures expected by Cochrane. Our primary outcomes were hepatitis C-related morbidity, serious adverse events, and health-related quality of life. Our secondary outcomes were all-cause mortality, ascites

Cochrane2017

119. Timing of Hepatitis C Virus Treatment in Liver Transplant Candidates in the Era of Direct-acting Antiviral Agents

Timing of Hepatitis C Virus Treatment in Liver Transplant Candidates in the Era of Direct-acting Antiviral Agents 29226102 2018 11 13 2225-0719 5 4 2017 Dec 28 Journal of clinical and translational hepatology J Clin Transl Hepatol Timing of Hepatitis C Virus Treatment in Liver Transplant Candidates in the Era of Direct-acting Antiviral Agents. 363-367 10.14218/JCTH.2017.00007 Chronic hepatitis C virus (HCV) infection remains the leading indication for liver transplantation (LT) in the United (...) States. While most patients with chronic HCV infection remain asymptomatic, up to one-third develop progressive liver disease resulting in cirrhosis. LT is often the only curative treatment once significant hepatic decompensation develops. However, antiviral therapy for HCV infection has advanced markedly in the past 5 years with the discovery and approval of direct-acting antiviral agents. These new regimens are well tolerated, of short duration and highly effective, unlike the traditional treatment

Journal of clinical and translational hepatology2017 Full Text: Link to full Text with Trip Pro

120. Outcomes of Transcatheter Versus Surgical Aortic Valve Implantation for Aortic Stenosis in Patients With Hepatic Cirrhosis

Outcomes of Transcatheter Versus Surgical Aortic Valve Implantation for Aortic Stenosis in Patients With Hepatic Cirrhosis 28803656 2017 08 14 2017 09 14 2017 09 14 1879-1913 120 7 2017 Oct 01 The American journal of cardiology Am. J. Cardiol. Outcomes of Transcatheter Versus Surgical Aortic Valve Implantation for Aortic Stenosis in Patients With Hepatic Cirrhosis. 1193-1197 S0002-9149(17)31129-3 10.1016/j.amjcard.2017.06.067 Current risk prediction tools for transcatheter aortic valve (...) implantation (TAVI) or surgical aortic valve replacement (SAVR) do not include variables associated with clinically significant hepatic disease. Accordingly, outcome data of TAVI or SAVR in patients with liver cirrhosis are limited. We sought to assess contemporary trends and outcomes of TAVI and SAVR in patients with liver cirrhosis using a national database. The Nationwide Inpatient Sample was used to identify patients with liver cirrhosis who underwent TAVI or SAVR between 2003 and 2014. Outcomes

EvidenceUpdates2017